SCHEMBL4640347

SCHEMBL4640347

CNC(=O)c1ccc(OBOc2ccc(C(=O)NC)c(Cl)c2)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.46
TYK2 P29597 1/20 0.46
FLT1 P17948 2/20 0.44
FLT4 P35916 2/20 0.44
KDR P35968 2/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11037222 0.83 TYK2 (0.62) JAK2TYK2FLT1FLT4KDR
SCHEMBL516293 0.82 ABL1 (0.46) JAK2TYK2FLT1FLT4KDR
SCHEMBL9938205 0.79 HPGD (0.61) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL4640337 0.78 KMT2A (0.47) JAK2TYK2ALDH1A1SMN1; SMN2RAB9A
SCHEMBL29833777 0.75 KDM4E (0.67) JAK2TYK2FLT1FLT4KDR
SCHEMBL4154496 0.75 KDM4E (0.67) JAK2TYK2FLT1FLT4KDR
SCHEMBL7706279 0.74 HPGD (0.59) FLT1FLT4KDRALDH1A1SMN1; SMN2
SCHEMBL3783986 0.74 PYGL (0.57) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL7970021 0.73 JAK2 (0.58) JAK2TYK2ALDH1A1SMN1; SMN2MEN1
SCHEMBL883798 0.73 HPGD (0.61) FLT1FLT4KDRRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255117-A1 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-10-16 US disclosed
WO-2008104597-A2 SULFONYLTRYPTOPHANOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-04 WO disclosed
EP-1964834-A1 Sulphonyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-03 EP disclosed
US-20080207728-A1 BICYCLIC ACYLTRYPTOPHANOLS BAYER SCHERING PHARMA AG (DE) 2008-08-28 US disclosed
EP-1956016-A1 Bicyclic acyltryptophanols Bayer Schering Pharma Aktiengesellschaft (DE) 2008-08-13 EP disclosed
WO-2008071455-A1 BICYCLIC ACYLTRYPTOPHANOLS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255117-A1 SULFONYLTRYPTOPHANOLS FSHR, NPY1R, GNRHR JAK2 1052/4885TYK2 1088/4885FLT1 803/4885
US-20080207728-A1 BICYCLIC ACYLTRYPTOPHANOLS FSHR, GNRHR, TPH1 JAK2 2355/4885TYK2 1743/4885FLT1 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.